On the involvement of calpains in the degradation of the tumor suppressor protein p53

被引:69
|
作者
Gonen, H
Shkedy, D
Barnoy, S
Kosower, NS
Ciechanover, A
机构
[1] TECHNION ISRAEL INST TECHNOL,DEPT BIOCHEM,IL-31096 HAIFA,ISRAEL
[2] TECHNION ISRAEL INST TECHNOL,RAPPAPORT FAMILY INST RES MED SCI,FAC MED,IL-31096 HAIFA,ISRAEL
[3] TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL
关键词
calpain; p53; ubiquitin; proteolysis;
D O I
10.1016/S0014-5793(97)00225-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A crude fraction that contains ubiquitin-protein ligases contains also a proteolytic activity of similar to 100 kDa that cleaves p53 to several fragments. The protease does not require ATP and is inhibited in the crude extract by an endogenous similar to 250 kDa inhibitor. The proteinase can be inhibited by chelating the Ca2+ ions, by specific cysteine proteinase inhibitors and by peptide aldehyde derivatives that inhibit calpains. Purified calpain demonstrates an identical activity that can be inhibited by calpastatin, the specific protein inhibitor of the enzyme. Thus, it appears that the activity we have identified in the extract is catalyzed by calpain. The calpain in the extract degrades also N-myc, c-Fos and c-Jun, but not lysozyme. In crude extract, the calpain activity can be demonstrated only when the molar ratio of the calpain exceeds that of its native inhibitor. Recent experimental evidence implicates both the ubiquitin proteasome pathway and calpain in the degradation of the tumor suppressor, and it was proposed that the two pathways may play a role in targeting the protein under various conditions. The potential role of the two systems in this important metabolic process is discussed. (C) 1997 Federation of European Biochemical Societies.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [41] Refolding and structural characterization of the human p53 tumor suppressor protein
    Bell, S
    Hansen, S
    Buchner, J
    BIOPHYSICAL CHEMISTRY, 2002, 96 (2-3) : 243 - 257
  • [42] MUTANT P53 TUMOR-SUPPRESSOR PROTEIN AS AN IMMUNOTHERAPEUTIC TARGET
    CARBONE, DP
    YANUCK, M
    WIEDENFELD, E
    CIERNIK, F
    FERNANDEZVINA, M
    PENDLETON, CD
    TSUKUI, T
    MINNA, JD
    BERZOFSKY, JA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 165 - 165
  • [43] The role of tumor suppressor protein p53 in oncolytic reovirus infection
    Pan, Da
    Marcato, Paola
    Shmulevitz, Maya
    Lee, Patrick
    CANCER RESEARCH, 2009, 69
  • [44] Protein methylation: a new mechanism of p53 tumor suppressor regulation
    Scoumanne, A.
    Chen, X.
    HISTOLOGY AND HISTOPATHOLOGY, 2008, 23 (09) : 1143 - 1149
  • [45] The regulation of interferon signaling system by p53 tumor suppressor protein
    Bezdzinska, A.
    Lasut-Szyszka, B.
    Rusin, M.
    FEBS OPEN BIO, 2022, 12 : 213 - 213
  • [46] PANCREATIC NEUROENDOCRINE CARCINOMAS EXPRESS THE P53 TUMOR SUPPRESSOR PROTEIN
    BARTZ, C
    ZISKE, C
    MOLLING, K
    WIEDENMANN, B
    GASTROENTEROLOGY, 1993, 104 (04) : A294 - A294
  • [47] ALTERED P53 TUMOR SUPPRESSOR GENE PROTEIN IN ACTINIC KERATOSIS
    ZIEGLER, A
    MARKS, R
    SHAPIRO, PE
    LEFFELL, DJ
    BRASH, DE
    CLINICAL RESEARCH, 1992, 40 (02): : A550 - A550
  • [48] Structural Bioinformatics and Molecular Dynamics of p53 Tumor Suppressor Protein
    Thayer, Kelly
    Slaw, Benjamin
    Han, In
    Quinn, Taylor
    FASEB JOURNAL, 2015, 29
  • [49] Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis
    Fuhrken, Peter G.
    Apostolidis, Pani A.
    Lindsey, Stephan
    Miller, William M.
    Papoutsakis, Eleftherios T.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (23) : 15589 - 15600
  • [50] Activation of p53 tumor suppressor protein by thymidine dinucleotides.
    Eller, MS
    Maeda, T
    Ostrom, K
    Gilchrest, BA
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) : 179 - 179